Avastin Plus Commonly Used Chemotherapies Improves The Time Breast Cancer Patie

< BACK TO HEALTH starstarstarstarstar   Community - Health Press Release
30th May 2009, 02:15am - Views: 634





Community Health Roche 1 image

Community Health Roche 2 image







Avastin Plus Commonly Used Chemotherapies Improves the Time Breast Cancer

Patients Live Without Their Disease Getting Worse


BASEL, May 29 /PRNewswire-AsiaNet/ --


    

    - RIBBON-1 Study Confirms Benefit of Avastin in Treating HER2-Negative

Breast Cancer


    - For Non-US, Non-UK and Non-Austrian Media

 

    Results from the phase III RIBBON-1 study presented today at ASCO showed

that patients with advanced HER2-negative breast cancer who were treated with

Avastin(R) (bevacizumab) plus the most commonly used chemotherapies lived

longer without their disease worsening (progression free survival or PFS),

compared to those being treated with chemotherapies alone. RIBBON-1 confirms

that Avastin can be safely and effectively combined with a range of

chemotherapies for first line treatment of HER2-negative metastatic breast

cancer, offering patients and physicians more treatment options.


    To view the Multimedia News Release, please click: 




    This is the first study to show clinical benefit for patients when

combining Avastin with an anthracycline-containing regimen and Xeloda(R)

(capecitabine), and the third trial (following E2100 and AVADO) to confirm

the efficacy and safety of Avastin in combination with standard

chemotherapies for the treatment of advanced breast cancer in the first line

setting.


    Key results from RIBBON-1 included:


    - Up to 55% increase in the chance of the patient living without the

    disease getting worse.


    - A significant increase in tumour shrinkage in patients that received

    Avastin (response rate = 51% vs. 37.9% for Avastin + anthracycline or

    taxane chemotherapy vs. chemotherapy alone).


    - There were no new safety signals for Avastin in RIBBON-1, confirming

    the safety and tolerability profile seen in previous studies.



    'These results are further proof that Avastin based therapy is part of

the armamentarium of treatment for patients with advanced breast cancer' said

Dr Nicholas Robert, M.D, Co-chair Breast Cancer Research Committee, U.S.

Oncology, Inc., investigator of the RIBBON-1 study. 'The growing body of

evidence supporting the combination of Avastin with commonly used

chemotherapy regimens, gives physicians more flexibility to tailor the most

appropriate course of Avastin based therapy for their patients.'


    Despite the treatment improvements that have already been

made, breast cancer continues to be the leading cause of cancer death in

women under the age of 55 and more than one million women are diagnosed each

year, leading to more than 500,000 deaths from the disease worldwide(1),(2).


    About the RIBBON-1 study


    RIBBON-1 is a global double blind, placebo-controlled, randomised phase

III trial including 1,237 patients who did not receive previous chemotherapy

for their HER2-negative locally recurrent or metastatic breast cancer.

 

    - The primary objective of RIBBON-1 was to demonstrate superiority in PFS

    of Avastin containing treatment arms compared to the control arms.


    - Secondary endpoints for the study included independently reviewed PFS,

    response rate, overall survival, 1-year survival, safety and

    tolerability.



    RIBBON-1 comprised of two independently powered treatment groups

investigating either Avastin or placebo in combination with 7 distinct

chemotherapy regimens:


    - Taxanes - docetaxel or protein bound paclitaxel

    - Anthracyclines - doxorubicin- or epirubicin-based regimen


    Standard anthracyline-based regimens included the following:


    

           - FEC (Fluorouracil (5FU), epirubicin and cyclophosphamide),

           - EC (epirubicin and cyclophosphamide),

           - AC (doxorubicin and cyclophosphamide),

           - FAC (Fluorouracil (5FU), doxorubicin and cyclophosphamide)

    - Xeloda (capecitabine)



    Avastin yielded superior PFS in both treatment groups.


    About Avastin


    Avastin is an antibody that specifically binds and blocks VEGF (vascular

endothelial growth factor). VEGF is the key driver of tumour angiogenesis -

an essential process of development and maintenance of blood vessels which is

required for a tumour to grow and to spread (metastasise) to other parts of

the body. Avastin's precise mode of action helps control tumour growth and

metastases with only a limited impact on side effects of chemotherapy.


    Avastin has proven survival benefits across multiple tumour types.

Avastin is approved in Europe for the treatment of the advanced stages of

four common types of cancer: colorectal cancer, breast cancer, lung cancer

and kidney cancer. These types of cancer collectively cause nearly 3 million

deaths each year. In the US, Avastin was the first anti-angiogenesis therapy

approved by the FDA and is now approved for the treatment of four tumour

types: breast, colorectal, glioblastoma, and non small cell lung cancer

(NSCLC).


    More than 500,000 patients have been treated with Avastin so far. A

comprehensive clinical programme with more than 450 clinical trials is

investigating the use of Avastin in various tumour types (including

colorectal, breast, lung, brain, gastric, ovarian, prostate and others) and

different settings (advanced or early stage disease).


    About Xeloda (capecitabine)


    Xeloda, capecitabine, is a highly effective targeted oral chemotherapy

Community Health Roche 3 image

offering patients a survival advantage when taken on its own or in

combination with other anticancer drugs. Xeloda uniquely activates the

cancer-killing agent 5-FU (5-fluorouracil) directly inside the cancer cells

so avoiding damage to healthy cells. Xeloda tablets can be taken by patients

in their own home, reducing the number of hospital visits.


    Licensed and marketed by Roche in more than 100 countries worldwide,

Xeloda has more than ten years of proven clinical experience providing an

effective and flexible treatment option to over 1.8 million people with

cancer. Xeloda is currently approved in metastatic colorectal cancer,

metastatic breast cancer, adjuvant colon cancer, advanced gastric cancer,

metastatic pancreatic cancer.


    All trademarks used or mentioned in this release are legally protected.


    References


    1. Garcia M et al. Global Cancer Facts & Figures. Atlanta, GA: American

Cancer Society, 2007.


    2. WHO Cancer Factsheet No.297 - updated July 2008. Last accessed 24



    For more information please contact:


    

    Irina Berechet

    Roche

    +41-79-865-98-50


    Dominic Elliston

    Galliard Healthcare

    +44-7717-502-860


    SOURCE: Roche

(WYE)To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article